XBIO vs PRPO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 26, 2026

XBIO

61.1
AI Score
VS
XBIO Wins

PRPO

44.7
AI Score

Investment Advisor Scores

XBIO

61score
Recommendation
BUY

PRPO

45score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric XBIO PRPO Winner
Revenue 1.47M 13.73M PRPO
Net Income -1.39M -1.66M XBIO
Net Margin -94.5% -12.1% PRPO
Operating Income -1.47M -2.03M XBIO
ROE -22.8% -11.3% PRPO
ROA -19.9% -7.8% PRPO
Total Assets 6.97M 21.32M PRPO
Current Ratio 7.43 1.77 XBIO

Relative Price Performance (Last 90 Days)

XBIO 1M: -47.3% · 3M: -21.4% PRPO 1M: -15.9% · 3M: -8.4%

Current Technical Phase

XBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 35

RSI (14): 34.8 · Price: $2.24

PRPO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 38

RSI (14): 37.6 · Price: $23.13

Fundamentals Snapshot

Metric XBIO PRPO
Market Cap — —
Forward P/E -6.6 15.4
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.1% 0.2%
Gross Margin 1.0% 0.4%
Operating Margin -1.5% -0.1%
EPS -1.15 -0.62
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, XBIO is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.